1. Targeting sirtuins for cancer therapy: epigenetics modifications and beyond.
- Author
-
Shen H, Qi X, Hu Y, Wang Y, Zhang J, Liu Z, and Qin Z
- Subjects
- Humans, Animals, Antineoplastic Agents therapeutic use, Antineoplastic Agents pharmacology, Molecular Targeted Therapy methods, Signal Transduction drug effects, Sirtuins metabolism, Neoplasms drug therapy, Neoplasms genetics, Neoplasms metabolism, Epigenesis, Genetic
- Abstract
Sirtuins (SIRTs) are well-known as nicotinic adenine dinucleotide
+ (NAD+ )-dependent histone deacetylases, which are important epigenetic enzymes consisting of seven family members (SIRT1-7). Of note, SIRT1 and SIRT2 are distributed in the nucleus and cytoplasm, while SIRT3, SIRT4 and SIRT5 are localized in the mitochondria. SIRT6 and SIRT7 are distributed in the nucleus. SIRTs catalyze the deacetylation of various substrate proteins, thereby modulating numerous biological processes, including transcription, DNA repair and genome stability, metabolism, and signal transduction. Notably, accumulating evidence has recently underscored the multi-faceted roles of SIRTs in both the suppression and progression of various types of human cancers. Crucially, SIRTs have been emerging as promising therapeutic targets for cancer therapy. Thus, in this review, we not only present an overview of the molecular structure and function of SIRTs, but elucidate their intricate associations with oncogenesis. Additionally, we discuss the current landscape of small-molecule activators and inhibitors targeting SIRTs in the contexts of cancer and further elaborate their combination therapies, especially highlighting their prospective utility for future cancer drug development., Competing Interests: Competing Interests: The authors have declared that no competing interest exists., (© The author(s).)- Published
- 2024
- Full Text
- View/download PDF